cdmo.directory
← Compare landing

Dipharma vs Kincell Bio

Side-by-side profile data from each company listing. Missing fields stay blank rather than filled with assumptions.

CategoryDipharmaKincell Bio
SummaryGlobal CDMO and API manufacturer with 600 employees, 4 cGMP plants, and 75+ years of experience in hazardous chemical synthesis, offering exclusive synthesis services and catalogue APIs with FDA, AIFA, and PMDA inspections since 1970.Leading cell therapy CDMO delivering GMP manufacturing, analytics, and CMC strategy from early development through commercial launch across purpose-built U.S. facilities.
Services
  • API Synthesis & Manufacturing
  • Process Development
  • Technology Transfer
  • CMC Analytical Development
  • Quality Control Testing
  • CMC Regulatory Submission Support
  • Cell Therapy Manufacturing
  • Process Development
  • CMC Analytical Development
  • Quality Control Testing
  • CMC Regulatory Submission Support
Modalities
  • Small Molecule
  • Cell Therapy
Development capabilities
  • Analytical method development
  • Analytical method development
Manufacturing capabilities
  • Drug Substance (DS)
  • Drug Product (DP)
  • Drug Substance (DS)
  • Drug Product (DP)
Locations
  • Headquarters, Milan, Lombardy, Italy
  • Commercial Office, United States
  • Commercial Office, China
  • Early CMC & Clinical Supply, Gainesville, FL, USA
  • Pivotal & Commercial Manufacturing, Research Triangle Park, NC, USA
CertificationsData not yet provided.Data not yet provided.

Find similar companies

Dipharma alternatives · Kincell Bio alternatives

Markdown mirror: /compare/dipharma/kincellbio.md